CD274 and non-small cell lung carcinoma: It is thus conceivable that TMB, particularly in combination with PD-L1 assessment, will shortly become a feasible and robust predictive tool [30], particularly as the immunotherapeutic approach now represents the cornerstone of the management of NSCLC cases lacking demonstrable targetable lesions [22].